Health News Releases

October 08, 2015 17:35

Delayed IPF Diagnosis Negatively Impacts Patients by Delaying Treatment According to Global Survey of Pulmonologists[1]

A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis (IPF) negatively impacts patients. 79% stat

October 08, 2015 15:00

ReSound® Brings Industry-Leading Hearing Aid Portfolio to EUHA 2015

ReSound is pleased to return to EUHA’s 60th International Congress of Hearing Aid Acousticians next week in Nuremberg, Germany, to showcase the industry’s most comprehensive portfolio of hearing solut

October 08, 2015 11:35

Cell Therapy Catapult Launches Cell History File

The Cell Therapy Catapult, the organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the

October 07, 2015 11:50

FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune in combination with temozolomide for the treatment of adult patients with newly diagnosed g

October 06, 2015 14:30

SafeCare Magazine Selects Joe Kiani as Person of the Year

SafeCare Magazine announced today that Joe Kiani, Founder of the Patient Safety Movement Foundation and CEO of Masimo, was awarded Person of the Year for 2015. This award recognizes and applauds the o

October 06, 2015 13:35

Replicor Announces Initiation of Recruitment for Its Phase IIb Clinical Trial with REP 2139-Mg or REP 2165-Mg in Combination with Viread® and Pegasys® or Zadaxin® in Patients with HBeAg Negative Chronic Hepatitis B Infection

Replicor announces that the recruitment of patients is underway for its second Phase II trial in Caucasian patients that will assess the safety and antiviral efficacy of REP 2139-Mg or REP 2165-Mg in

October 02, 2015 11:00

HOYA Group PENTAX Medical Announces Expansion into Endoscopic Therapy through Strategic Investment in Creo Medical Ltd.

HOYA Group PENTAX Medical has entered into an agreement to invest in Creo Medical Ltd., a leading electrosurgical energy devices company based in the U.K. The official documents formalizing the agreem

October 02, 2015 03:10

ReSound® Launches New Wireless Hearing Aid, Bringing Industry-Leading Connectivity and Sound Quality to Wearers Where Budget Matters

ReSound today announced the global launch of the ReSound Enya family of hearing aids, making the company’s industry-leading, innovative hearing technologies accessible to even more people living with

September 30, 2015 17:20

New data demonstrate sustained long-term efficacy of OFEV®* on slowing disease progression and safety in patients with IPF

An interim analysis of the INPULSIS®-ON extension trial has confirmed the efficacy and safety of OFEV®* (nintedanib) previously observed in the INPULSIS® trials.[1] The results were presented at the E

September 30, 2015 11:55

Takeda Selected for the Sixth Consecutive Year for Dow Jones Sustainability Asia Pacific Index

Takeda Pharmaceutical Company Ltd. (“Takeda”) (TOKYO: 4502) (http://goo.gl/eX9kbP) has been selected for the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific) for the sixth consecutive y

September 30, 2015 11:25

Annie Hai-yuan Lo Elected to Quintiles Transnational Holdings Inc. Board of Directors

Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) announced today that Annie Hai-yuan Lo, has been appointed to its Board of Directors, effective immediately. Ms. Lo will

September 30, 2015 00:55

Quintiles Recognized as Phase IV Services Leader for Third Consecutive Year

Quintiles has been named the market leader in Phase IV services for the third year in a row, according to the 2015 CRO Quality Benchmarking - Phase IV Service Providers Report (http://goo.gl/fM6Iqu) f

September 30, 2015 00:40

Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis

Takeda Pharmaceutical Company Limited (TOKYO:4502) (www.takeda.com/investor-information) today obtained the New Drug Application approval for Copaxone® Subcutaneous Injection 20 mg Syringe (generic na

September 29, 2015 17:25

Masimo Donates $5 Million in Medical Equipment to Assist Jordan in Providing Healthcare to Over 1 Million Syrian Refugees

Masimo (www.masimo.com) (NASDAQ: MASI) announced progress today at the 2015 Clinton Global Initiative Annual Meeting towards its commitment to donate $5 million in Signal Extraction Technology® Pulse

September 29, 2015 13:35

COPD: New Data Support Role of Spiolto® Respimat® as 1st-line Maintenance Therapy and Show Superiority over LABA/ICS

Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A post-hoc analysis from OTEMTO® 1&2 indicates that Spiol

September 29, 2015 13:25

ECC 2015: GIOTRIF® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib* compared

September 29, 2015 13:15

VARGATEF® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, further data to support the efficacy of VARGATEF® (nintedanib*) in combination with docetaxel for the tre

September 29, 2015 13:00

Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma

Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab* for the treatment of Merkel c

September 29, 2015 12:50

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

Today, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending European approval of idarucizumab (to be marketed as

September 25, 2015 16:40

Celgene’s VIDAZA® (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with Acute Myeloid Leukaemia

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human U

September 25, 2015 10:15

Merck and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab

As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab*, an investigational immune checkpoint inhibitor, the companies have announced today tha

September 23, 2015 11:25

Takeda to Highlight Ixazomib Clinical Development Program at Upcoming International Myeloma Workshop

Takeda Pharmaceutical Company Limited (TSE: 4502, http://goo.gl/eX9kbP) today announced that it will highlight the ixazomib clinical development program during multiple poster sessions at the upcoming

September 21, 2015 17:20

Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD

Boehringer Ingelheim and BioMed X announced today that they have successfully applied a crowdsourcing approach to establish a research team of outstanding scientists from around the world with bright

September 21, 2015 15:35

ERS 2015: Landmark year for Boehringer Ingelheim’s respiratory portfolio - new data for COPD, IPF and asthma treatments

Boehringer Ingelheim will present new data from its broad respiratory portfolio, which includes recently approved Spiolto® Respimat® (tiotropium/olodaterol) for COPD, OFEV® (nintedanib) for IPF and Sp

September 18, 2015 13:20

Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Boehringer Ingelheim and Eli Lilly and Company’s (NYSE: LLY) Jardiance® (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or

News by Region

News by Industry